2024
Right Ventricular Dysfunction in Patients Undergoing High-Risk PCI with Impella
Rommel K, Bonnet G, Bellumkonda L, Lansky A, Zhao D, Thompson J, Zhang Y, Redfors B, Lurz P, Granada J, Bharadwaj A, Basir M, O'Neill W, Burkhoff D. Right Ventricular Dysfunction in Patients Undergoing High-Risk PCI with Impella. Journal Of Cardiac Failure 2024, 30: 1244-1254. PMID: 39389734, DOI: 10.1016/j.cardfail.2024.08.001.Peer-Reviewed Original ResearchConceptsRight ventricular dysfunctionHigh-risk percutaneous coronary interventionVentricular dysfunctionAssociated with right ventricular dysfunctionTricuspid annular plane systolic excursionConcomitant right ventricular dysfunctionLower left ventricular ejection fractionUnfavorable long-term prognosisAnnular plane systolic excursionClinical outcomes of patientsAbsence of right ventricular dysfunctionImpella supportPredictor of 1-year mortalityMultivariate Cox regression analysisIncidence of hypotensive episodesEchocardiography core laboratorySevere RV dilatationBlood urea nitrogen levelsRV function assessmentVentricular ejection fractionOutcomes of patientsRates of in-hospital mortalityHigher blood urea nitrogen levelsLong-term prognosisProportion of patientsMoving Beyond Devices to Patient Selection A New Frontier in Stroke Prevention After TAVR
Ahmad Y, Lansky A. Moving Beyond Devices to Patient Selection A New Frontier in Stroke Prevention After TAVR. JACC Cardiovascular Interventions 2024, 17: 1691-1692. PMID: 39048256, DOI: 10.1016/j.jcin.2024.06.017.Peer-Reviewed Original ResearchTreatment of Acute Myocardial Infarction and Cardiogenic Shock: Outcomes of the RECOVER III Postapproval Study by Society of Cardiovascular Angiography and Interventions Shock Stage
Hanson I, Rusia A, Palomo A, Tawney A, Pow T, Dixon S, Meraj P, Sievers E, Johnson M, Wohns D, Ali O, Kapur N, Grines C, Burkhoff D, Anderson M, Lansky A, Naidu S, Basir M, O'Neill W. Treatment of Acute Myocardial Infarction and Cardiogenic Shock: Outcomes of the RECOVER III Postapproval Study by Society of Cardiovascular Angiography and Interventions Shock Stage. Journal Of The American Heart Association 2024, 13: e031803. PMID: 38293995, PMCID: PMC11056148, DOI: 10.1161/jaha.123.031803.Peer-Reviewed Original ResearchConceptsSociety for Cardiovascular AngiographyCardiovascular AngiographyAcute myocardial infarctionIII studiesCardiogenic shockStage CPercutaneous coronary interventionMyocardial infarctionPostapproval studiesCoronary interventionImpella supportKaplan-Meier survival curve analysisSociety of Cardiovascular AngiographyThirty-day survivalResponse to therapyCohort of patientsStudy of patientsPredictors of mortalitySurvival curve analysisTreatment of acute myocardial infarctionPredictive of mortalitySeverity of shockSingle-armThirty-dayStaging systemIntravascular Imaging–Guided Versus Angiography‐Guided Percutaneous Coronary Intervention: A Systematic Review and Meta‐Analysis of Randomized Trials
Sreenivasan J, Reddy R, Jamil Y, Malik A, Chamie D, Howard J, Nanna M, Mintz G, Maehara A, Ali Z, Moses J, Chen S, Chieffo A, Colombo A, Leon M, Lansky A, Ahmad Y. Intravascular Imaging–Guided Versus Angiography‐Guided Percutaneous Coronary Intervention: A Systematic Review and Meta‐Analysis of Randomized Trials. Journal Of The American Heart Association 2024, 13: e031111. PMID: 38214263, PMCID: PMC10926835, DOI: 10.1161/jaha.123.031111.Peer-Reviewed Original ResearchConceptsAdverse cardiac eventsPercutaneous coronary interventionAngiography-guided percutaneous coronary interventionTarget vessel revascularizationTarget-lesion revascularizationCardiac eventsCardiac deathImaging-guided percutaneous coronary interventionWeighted mean follow-up durationMeta-analysisPrimary outcomeMean follow-up durationStent thrombosisMeta-analysis of randomized trialsStudy-level meta-analysisComplex lesion subsetsIntravascular imagingAll-cause deathRandom-effects meta-analysisStandard of careIntention-to-treat principleUpdates of clinical guidelinesMixed-effects meta-regressionComplex percutaneous coronary interventionIntravascular imaging-guided percutaneous coronary intervention
2023
Targeted therapy with a localised abluminal groove, low-dose sirolimus-eluting, biodegradable-polymer coronary stent - five-year results of the TARGET All Comers randomised clinical trial.
Lansky A, Xu B, Baumbach A, Kelbæk H, van Royen N, Zheng M, Knaapen P, Slagboom T, Johnson T, Vlachojannis G, Arkenbout K, Holmvang L, Janssens L, Brugaletta S, Naber C, Schmitz T, Anderson R, Rittger H, Berti S, Barbato E, Toth G, Maillard L, Valina C, Buszman P, Thiele H, Schächinger V, Wijns W. Targeted therapy with a localised abluminal groove, low-dose sirolimus-eluting, biodegradable-polymer coronary stent - five-year results of the TARGET All Comers randomised clinical trial. EuroIntervention 2023, 19: e844-e855. PMID: 37860860, PMCID: PMC10687649, DOI: 10.4244/eij-d-23-00409.Peer-Reviewed Original ResearchConceptsTarget lesion failureDP-EES groupPercutaneous coronary interventionBP-SES groupBP-SESPrimary endpointDP-EESRate of TLFBiodegradable polymer sirolimus-eluting stentsST-elevation myocardial infarction (STEMI) presentationMyocardial infarction presentationSirolimus-eluting stentsFive-year resultsLong-term safetyAbluminal grooveLesion failureSecondary endpointsComers populationCoronary interventionMyocardial ischaemiaStent implantationClinical trialsTargeted therapyLandmark analysisStudy outcomesPredictors of Cerebral Embolic Debris During Transcatheter Aortic Valve Replacement: The SafePass 2 First-in-Human Study
Grubman D, Ahmad Y, Leipsic J, Blanke P, Pasupati S, Webster M, Nazif T, Parise H, Lansky A. Predictors of Cerebral Embolic Debris During Transcatheter Aortic Valve Replacement: The SafePass 2 First-in-Human Study. The American Journal Of Cardiology 2023, 207: 28-34. PMID: 37722198, DOI: 10.1016/j.amjcard.2023.08.137.Peer-Reviewed Original ResearchConceptsTranscatheter aortic valve replacementAortic valve replacementValve replacementAtrial fibrillationHuman studiesEmbolic protection device useHigh embolic riskPrimary end pointHigh-risk patientsIndependent core laboratorySelf-expanding valvesComputed tomography angiographyProtection device useCerebral embolizationCerebrovascular eventsEmbolic riskAcute thrombusEmbolic burdenAngiography featuresTechnical successTomography angiographyEmbolic debrisValve useCore laboratoryEnd pointEffect of antecedent statin usage on conduction disturbances and arrhythmias after transcatheter aortic valve replacement
Shah T, Maarek R, See C, Huang H, Wang Y, Parise H, Forrest J, Lansky A. Effect of antecedent statin usage on conduction disturbances and arrhythmias after transcatheter aortic valve replacement. Cardiovascular Revascularization Medicine 2023, 59: 3-8. PMID: 37573173, DOI: 10.1016/j.carrev.2023.07.022.Peer-Reviewed Original ResearchConceptsAtrial fibrillationConduction disturbancesPrimary endpointStatin usersPacemaker placementRate of AFTranscatheter aortic valve replacementNew atrial fibrillationNew conduction disturbancesPersistent conduction disturbancesAortic valve replacementLong-term prognosisSmall retrospective studiesSignificant differencesPrior pacemakerIndex hospitalizationIntensity statinsValve replacementConsecutive patientsPropensity matchingProcedural complicationsStatin regimenRetrospective studyStatin usageCardiac proceduresSex Differences in pLVAD-Assisted High-Risk Percutaneous Coronary Intervention Insights From the PROTECT III Study
Shah T, Abu-Much A, Batchelor W, Grines C, Baron S, Zhou Z, Li Y, Maini A, Redfors B, Hussain Y, Wollmuth J, Basir M, O'Neill W, Lansky A. Sex Differences in pLVAD-Assisted High-Risk Percutaneous Coronary Intervention Insights From the PROTECT III Study. JACC Cardiovascular Interventions 2023, 16: 1721-1729. PMID: 37409991, DOI: 10.1016/j.jcin.2023.04.036.Peer-Reviewed Original ResearchConceptsHigh-risk percutaneous coronary interventionFemale patientsIII studySex-based differencesImmediate PCISYNTAX scoreClinical outcomesMyocardial infarctionStroke/transient ischemic attackWorse renal functionAcute limb ischemiaTransient ischemic attackSex differencesPercutaneous coronary interventionAcute myocardial infarctionHigher ejection fractionCause deathCoronary complicationsIschemic attackMajor bleedingNonfemoral accessPercutaneous CoronaryPrior strokeCerebrovascular eventsVascular complicationsImpact of New‐Onset Conduction Disturbances following Transcatheter Aortic Valve Replacement on Outcomes: A Single‐Center Study
See C, Wang Y, Huang H, Parise H, Yang Y, Tirziu D, Francese D, Papoutsidakis N, Bader E, Kaple R, Cleman M, Lansky A, Forrest J. Impact of New‐Onset Conduction Disturbances following Transcatheter Aortic Valve Replacement on Outcomes: A Single‐Center Study. Journal Of Interventional Cardiology 2023, 2023: 5390338. PMID: 37292113, PMCID: PMC10247319, DOI: 10.1155/2023/5390338.Peer-Reviewed Original ResearchMeSH KeywordsAortic ValveAortic Valve StenosisHumansRetrospective StudiesRisk FactorsTranscatheter Aortic Valve ReplacementTreatment OutcomeConceptsTranscatheter aortic valve replacementNew-onset conduction disturbancesAortic valve replacementPersistent conduction disturbancesConduction disturbancesValve replacementSurgical aortic valve replacementSingle-center retrospective analysisYale-New Haven HospitalSingle-center studyCause mortality ratesCause mortality riskLong-term outcomesNew Haven HospitalPeriprocedural factorsAortic stenosisConsecutive patientsTAVR proceduresTerm outcomesRetrospective analysisMortality riskMortality ratePatientsOutcomesPatient's ECGEffects of Elective Coronary Revascularization vs Medical Therapy Alone on Noncardiac Mortality A Meta-Analysis
Navarese E, Lansky A, Farkouh M, Grzelakowska K, Bonaca M, Gorog D, Raggi P, Kelm M, Yeo B, Umińska J, Curzen N, Kubica J, Wijns W, Kereiakes D. Effects of Elective Coronary Revascularization vs Medical Therapy Alone on Noncardiac Mortality A Meta-Analysis. JACC Cardiovascular Interventions 2023, 16: 1144-1156. PMID: 37225285, DOI: 10.1016/j.jcin.2023.02.030.Peer-Reviewed Original ResearchMeSH KeywordsBayes TheoremHeartHumansRandomized Controlled Trials as TopicReproducibility of ResultsSyndromeTreatment OutcomeConceptsChronic coronary syndromeElective coronary revascularizationNoncardiac mortalityMedical therapyCoronary revascularizationTrial sequential analysisCumulative Z-curveRate ratioA Meta-AnalysisRandom-effects modelMeta-analysis findingsCoronary syndromeISCHEMIA trialRandomized trialsTrial evidenceRevascularizationTreatment groupsPrespecified endpointsMeta-AnalysisPatientsMortalityFutility boundariesDeath rateTrialsTreatment effectsProspective, randomized, multicenter clinical study comparing a self-expanding covered stent to percutaneous transluminal angioplasty for treatment of upper extremity hemodialysis arteriovenous fistula stenosis
Dolmatch B, Cabrera T, Pergola P, Balamuthusamy S, Makris A, Cooper R, Moore E, Licht J, Macaulay E, Maleux G, Pfammatter T, Settlage R, Cristea E, Lansky A, Investigators A, Dolmatch B, Goh G, Hawkins S, Macaulay E, Spark I, de Graff R, Deutschmann H, Kickuth R, Maleux G, Pfammatter T, Kirksey L, Mendes R, Aruny J, Ali V, Cabrera T, Pergola P, Sharma D, Moore E, Shah H, Dwyer A, Yee D, Teng W, Cooper R, Balamuthusamy S, Lipkowitz G, Saad T, Licht J, Makris A, Rogers T, Burgess J, Hoggard J. Prospective, randomized, multicenter clinical study comparing a self-expanding covered stent to percutaneous transluminal angioplasty for treatment of upper extremity hemodialysis arteriovenous fistula stenosis. Kidney International 2023, 104: 189-200. PMID: 36990214, DOI: 10.1016/j.kint.2023.03.015.Peer-Reviewed Original ResearchConceptsTarget lesion primary patencyAccess circuit primary patencyPercutaneous transluminal angioplastyTarget lesion reinterventionPrimary patencyTransluminal angioplastyArteriovenous fistulaAVF stenosisAdditional clinical outcomesCircuit primary patencyCovered stent groupLesion primary patencyMulticenter clinical studyHemodialysis arteriovenous fistula stenosisArteriovenous fistula stenosisHemodialysis patientsPrimary outcomeRandomized studyClinical outcomesAVF dysfunctionStent groupClinical studiesFistula stenosisSix monthsPatientsRevascularisation, periprocedural events and survival - and the survival of the randomised controlled trial.
Lansky A, Ahmad Y. Revascularisation, periprocedural events and survival - and the survival of the randomised controlled trial. EuroIntervention 2023, 18: 1218-1219. PMID: 36939109, PMCID: PMC10018286, DOI: 10.4244/eij-e-23-00004.Peer-Reviewed Original ResearchMeSH KeywordsCoronary Artery BypassHumansMyocardial RevascularizationTreatment OutcomeVascular Surgical ProceduresColchicine and high-intensity rosuvastatin in the treatment of non-critically ill patients hospitalised with COVID-19: a randomised clinical trial
Shah T, McCarthy M, Nasir I, Archer H, Ragheb E, Kluger J, Kashyap N, Paredes C, Patel P, Lu J, Kandel P, Song C, Khan M, Huang H, Haq F, Ahmad R, Howes C, Cambi B, Lancaster G, Cleman M, Dela Cruz C, Parise H, Lansky A. Colchicine and high-intensity rosuvastatin in the treatment of non-critically ill patients hospitalised with COVID-19: a randomised clinical trial. BMJ Open 2023, 13: e067910. PMID: 36828654, PMCID: PMC9971831, DOI: 10.1136/bmjopen-2022-067910.Peer-Reviewed Original ResearchMeSH KeywordsBrain IschemiaColchicineCOVID-19FemaleHumansMaleMiddle AgedRosuvastatin CalciumSARS-CoV-2StrokeTreatment OutcomeConceptsStandard of careHigh-intensity rosuvastatinElectronic medical recordsCOVID-19 diseaseMedical recordsPrimary endpointThromboembolic eventsYale New Haven Health SystemSevere COVID-19 diseaseCOVID-19Prespecified primary endpointVenous thromboembolic eventsRisk of progressionCombination of colchicineSafety monitoring boardCare armHispanics/LatinosTherapeutic anticoagulationIndex hospitalisationIll patientsMedian ageFuture trialsEffect of colchicineClinical trialsMonitoring boardPublic Reporting of Stroke After Transcatheter Aortic Valve Replacement A Cautionary Tale ∗
Lansky A, Ahmad Y. Public Reporting of Stroke After Transcatheter Aortic Valve Replacement A Cautionary Tale ∗. JACC Cardiovascular Interventions 2023, 16: 177-178. PMID: 36697153, DOI: 10.1016/j.jcin.2022.11.010.Peer-Reviewed Original Research
2022
Intravascular Imaging for Guiding In‐Stent Restenosis and Stent Thrombosis Therapy
Erdogan E, Bajaj R, Lansky A, Mathur A, Baumbach A, Bourantas C. Intravascular Imaging for Guiding In‐Stent Restenosis and Stent Thrombosis Therapy. Journal Of The American Heart Association 2022, 11: e026492. PMID: 36326067, PMCID: PMC9750080, DOI: 10.1161/jaha.122.026492.Peer-Reviewed Original ResearchConceptsPercutaneous coronary interventionCoronary interventionStent failureStent restenosisStent thrombosisSecond-generation drug-eluting stentsConventional percutaneous coronary interventionHigh-risk patientsBetter clinical outcomesLong-term outcomesDrug-eluting stentsCumulative incidenceClinical outcomesWorse prognosisProcedural resultsComplex anatomyEndovascular devicesRestenosisTherapyStent technologyDrug kineticsIntravascular imagingTreatment planningNeointima tissueThrombosisImpella Versus Intra-Aortic Balloon Pump for High-Risk PCI: A Propensity-Adjusted Large-Scale Claims Dataset Analysis
Lansky AJ, Tirziu D, Moses JW, Pietras C, Ohman EM, O'Neill WW, Ekono MM, Grines CL, Parise H. Impella Versus Intra-Aortic Balloon Pump for High-Risk PCI: A Propensity-Adjusted Large-Scale Claims Dataset Analysis. The American Journal Of Cardiology 2022, 185: 29-36. PMID: 36210212, DOI: 10.1016/j.amjcard.2022.08.032.Peer-Reviewed Original ResearchConceptsHigh-risk percutaneous coronary interventionIntra-aortic balloon pumpPercutaneous coronary interventionAcute kidney injuryCardiogenic shockMyocardial infarctionIABP supportKidney injuryBalloon pumpImproved survivalPropensity adjustmentAcute ST-elevation myocardial infarctionST-elevation myocardial infarctionIndex hospitalization lengthLess myocardial infarctionPremier Healthcare DatabaseHospital myocardial infarctionPropensity-adjusted analysisMechanical circulatory supportMechanical support devicesImpella useHospital survivalIndex hospitalizationCoronary interventionReal-world practiceSafety and performance of a novel cerebral embolic protection device for transcatheter aortic valve implantation: the PROTEMBO C Trial.
Jagielak D, Targonski R, Frerker C, Abdel-Wahab M, Wilde J, Werner N, Lauterbach M, Leick J, Grygier M, Misterski M, Erglis A, Narbute I, Witkowski AR, Adam M, Frank D, Gatto F, Schmidt T, Lansky AJ. Safety and performance of a novel cerebral embolic protection device for transcatheter aortic valve implantation: the PROTEMBO C Trial. EuroIntervention 2022, 18: 590-597. PMID: 35608032, PMCID: PMC10241272, DOI: 10.4244/eij-d-22-00238.Peer-Reviewed Original ResearchConceptsTranscatheter aortic valve implantationAortic valve implantationLesion volumeValve implantationTechnical successC trialSingle lesionCerebral embolic protection devicesPerformance endpointBrain diffusion-weighted magnetic resonance imagingLarge single lesionsPrimary safety endpointBrain lesion volumeDiffusion-weighted magnetic resonance imagingCerebral protection systemSingle-arm studyEmbolic protection devicesPrimary performance endpointRate of deathMagnetic resonance imagingTAVI casesTAVI patientsVARC-2Cerebrovascular eventsPrimary endpointDevelopment and validation of an automated algorithm for end point adjudication for a large U.S. national registry
Friedman DJ, Pierre D, Wang Y, Gambone L, Koutras C, Segawa C, Farb A, Vemulapalli S, Varosy PD, Masoudi FA, Lansky A, Curtis JP, Freeman JV. Development and validation of an automated algorithm for end point adjudication for a large U.S. national registry. American Heart Journal 2022, 254: 102-111. PMID: 36007567, DOI: 10.1016/j.ahj.2022.08.006.Peer-Reviewed Original ResearchMeSH KeywordsAftercareAtrial AppendageAtrial FibrillationHumansIschemic Attack, TransientPatient DischargeRegistriesStrokeTreatment OutcomeConceptsEnd point adjudicationCEC adjudicationEnd pointLarge registriesClinical trialsNational Cardiovascular Data RegistryMajor vascular complicationsU.S. National RegistryPost-discharge eventsAgreement rateMajor bleedingNeurologic eventsVascular complicationsNational registryEvent adjudicationData registryRegistryCommittee's evaluationsPercent agreementGold standardAgreement thresholdHospitalTrialsFurther confirmationBleedingLeft Ventricular Remodeling After Anterior-STEMI PCI: Imaging Observations in the Door-to-Unload (DTU) Pilot Trial.
O'Neill WW, Wang DD, Polak S, Moses JW, Josephy N, Koenig G, Kim RJ, Lansky A, Bellumkonda L, Douglas PS, Kapur NK. Left Ventricular Remodeling After Anterior-STEMI PCI: Imaging Observations in the Door-to-Unload (DTU) Pilot Trial. Journal Of Invasive Cardiology 2022, 34: e611-e619. PMID: 35830361, DOI: 10.25270/jic/21.00401.Peer-Reviewed Original ResearchConceptsCardiac magnetic resonanceLV ejection fractionInfarct sizeLeft ventricularLV unloadingEjection fractionPilot trialGroup 2Group 1ST-segment elevation myocardial infarction (STEMI) patientsImproved LV ejection fractionElevation myocardial infarction patientsLV end-diastolic volumeMajor cardiovascular outcomesPercutaneous coronary interventionMyocardial infarction patientsEnd-diastolic volumeEnd-systolic volumeAnterior STEMIEchocardiographic LVEFCardiogenic shockCardiovascular outcomesEchocardiographic parametersImmediate reperfusionCoronary interventionRandomized Trial of Chocolate Touch Compared With Lutonix Drug-Coated Balloon in Femoropopliteal Lesions (Chocolate Touch Study)
Shishehbor MH, Zeller T, Werner M, Brodmann M, Parise H, Holden A, Lichtenberg M, Parikh SA, Kashyap VS, Pietras C, Tirziu D, Ardakani S, Beschorner U, Krishnan P, Niazi KA, Wali AU, Lansky AJ. Randomized Trial of Chocolate Touch Compared With Lutonix Drug-Coated Balloon in Femoropopliteal Lesions (Chocolate Touch Study). Circulation 2022, 145: 1645-1654. PMID: 35377157, DOI: 10.1161/circulationaha.122.059646.Peer-Reviewed Original ResearchConceptsLutonix drug-coated balloonDrug-coated balloonsEnd pointPrimary efficacy end pointPrimary safety end pointIndependent clinical events committeeIschemic rest painPrimary efficacy rateEfficacy end pointPrimary end pointSafety end pointClinical events committeeMajor adverse eventsRate of restenosisDrug-Coated BalloonNoninferiority end pointSafety event rateAverage lesion lengthMajor amputationPopliteal diseaseRest painBailout stentingEfficacy ratePrimary patencyAdverse events